Skip to main content
SpringerLink
Log in

Fidaxomicin or vancomycin for CDAD: similar total costs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2014 US dollars

Reference

  • Reveles KR, et al. Fidaxomicin versus Vancomycin as a First-Line Treatment for Clostridium difficile-Associated Diarrhea (CDAD) in Specific Patient Populations: A Pharmacoeconomic Evaluation. Pharmacotherapy : 17 Oct 2017. Available from: URL: http://doi.org/10.1002/phar.2049

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fidaxomicin or vancomycin for CDAD: similar total costs. PharmacoEcon Outcomes News 790, 14 (2017). https://doi.org/10.1007/s40274-017-4459-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4459-9

Search

Navigation